CD276 and macrophage activation syndrome: This quality of B7H3.CAR EBVSTs may distinguish them from other CAR T-cell therapies which have been linked to significant incidence of CRS, hemophagocytic lymphohistiocytosis/macrophage activation syndrome, and Immune effector Cell-Associated Neurotoxicity Syndrome (51).